<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03274453</url>
  </required_header>
  <id_info>
    <org_study_id>12-02202</org_study_id>
    <nct_id>NCT03274453</nct_id>
  </id_info>
  <brief_title>A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion</brief_title>
  <official_title>A Prospective, Randomized, Double Blinded Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the proposed study is to examine the effectiveness of low dose postoperative
      ketamine infusion as an analgesic adjuvant to morphine pca in opioid tolerant and opioid
      na√Øve patients after major spine surgery. Primary endpoints of the study are to determine the
      effectiveness of postoperative ketamine infusion in for the reduction of postoperative pain
      and opioid requirements.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2012</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">November 1, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of postoperative ketamine infusion in for the reduction of postoperative pain</measure>
    <time_frame>Up to 24 Hours</time_frame>
    <description>Numeric pain scales will be recorded in conjunction with evaluation of pca pain scores at arrival in PACU, then every 30min during the first 2 hours in PACU, then every 2 hours on the floor during the first 24 hours after surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Spinal Fusion</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine (or matching saline).
Infusion will be maintained for 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine (or matching saline).
Infusion will be maintained for 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>0.12 mg/kg/hr of ketamine post surgery</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0.12 mg/kg/hr of saline post surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult and teenage (&gt;/=16) male or female who will undergo surgery for multilevel (&gt;4
             level) spinal fusion from a posterior approach with general anesthesia, and who are
             fluent English speakers such that they can complete the pain score and satisfaction
             questionnaires whose scores are a critical outcome variable.

          -  If female, subject is non-lactating and is either:

          -  Not of childbearing potential

          -  Of childbearing potential but is not pregnant at time of baseline as determined by
             pre-surgical pregnancy testing.

          -  Subject is ASA physical status 1, 2, or 3.

        Exclusion Criteria:

          -  anxiety

          -  psychiatric disorder

          -  Allergy or sensitivity to ketamine or dilaudid

          -  Deemed un-acceptable by study team

          -  Cognitively impaired (by history)

          -  Subject requires chronic antipsychotic medication

          -  Subject known to be in liver failure

          -  Subject for whom opioids or ketamine are contraindicated

          -  Patients with narrow angle glaucoma

          -  Patients with a history of psychosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsten Boenigk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirsten.Boenigk@nyumc.org</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 24, 2017</submitted>
    <returned>December 19, 2017</returned>
    <submitted>May 15, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

